Clinical usefulness of RT-PCR detection of hematogenous prostate cancer spread.
Understaging is commonly associated with therapeutic failure of surgical intervention in apparently localized prostate cancers. Methods that specifically detect prostate cancer cells in the circulation may be able to identify metastatic cancers and thus aid in the selection of the most adequate therapy. The high sensitivity and specificity of the reverse transcriptase-polymerase chain reaction (RT-PCR) encouraged various groups to investigate the mRNA expression of prostate-specific markers in the peripheral blood of patients with prostate cancer. However, probably due to methodological differences, many contradictory results have been obtained with the markers studied so far: prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSM). For this reason, clinical decisions should not be based yet on RT-PCR results. Future research and long-term follow-up on the patients may point out whether RT-PCR assays, following appropriate standardization, will have an additive value in prostate cancer staging and in prediction of tumor progression.
Verkaik
N S
NS
Schröder
F H
FH
Romijn
J C
JC
D000954:Antigens, Surface; D014408:Biomarkers, Tumor / Q000097:blood*; D002268:Carboxypeptidases / Q000097:blood; D043425:Glutamate Carboxypeptidase II; D006801:Humans; D008297:Male; D009360:Neoplastic Cells, Circulating; D016133:Polymerase Chain Reaction; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology*
D000954:Antigens, Surface; D014408:Biomarkers, Tumor; D002268:Carboxypeptidases; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II; D017430:Prostate-Specific Antigen